Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial
Open accessAbstract
Preclinical evidence demonstrates that senescent cells accumulate with aging and that senolytics delay multiple age-related morbidities, including bone loss. Thus, we conducted a phase 2 randomized controlled trial of intermittent administration of the senolytic combination dasatinib plus quercetin (D + Q) in postmenopausal women (n = 60 participants). The primary endpoint, percentage changes at 20 weeks in the bone resorption marker C-terminal telopeptide of type 1 collagen (CTx), did not differ between groups (median (interquartile range), D + Q -4.1% (-13.2, 2.6), control -7.7% (-20.1, 14.3); P = 0.611). The secondary endpoint, percentage changes in the bone formation marker procollagen type 1 N-terminal propeptide (P1NP), increased significantly (relative to control) in the D + Q group at both 2 weeks (+16%, P = 0.020) and 4 weeks (+16%, P = 0.024), but was not different from control at 20 weeks (-9%, P = 0.149). No serious adverse events were observed. In exploratory analyses, the skeletal response to D + Q was driven principally by women with a high senescent cell burden (highest tertile for T cell p16 (also known as CDKN2A) mRNA levels) in which D + Q concomitantly increased P1NP (+34%, P = 0.035) and reduced CTx (-11%, P = 0.049) at 2 weeks, and increased radius bone mineral density (+2.7%, P = 0.004) at 20 weeks. Thus, intermittent D + Q treatment did not reduce bone resorption in the overall group of postmenopausal women. However, our exploratory analyses indicate that further studies are needed testing the hypothesis that the underlying senescent cell burden may dictate the clinical response to senolytics. ClinicalTrials.gov identifier: NCT04313634 .
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
- Finding
In exploratory analyses, the highest tertile of T cell p16 mRNA levels showed increases in P1NP and reductions in CTx after D + Q treatment.
“serum P1NP increased at 2 weeks in the T3 D + Q group (relative to control, +34%, P = 0.035)”
Quote in the paperNot yet classified - Finding
The authors conclude that the p16_variant 5 assay more effectively identified individuals likely to have a favorable skeletal response to D + Q than the p16_variant 1 + 5 assay.
“the p16_variant 5 assay appeared to more effectively identify individuals likely to have a favorable skeletal response to D + Q compared with the p16_variant 1 + 5 assay.”
Quote in the paperNot yet classified - Finding
The trial found that D + Q increased the bone formation marker P1NP at 2 and 4 weeks, but not at 20 weeks, in the overall group.
“the secondary endpoint, percentage changes in the bone formation marker procollagen type 1 N-terminal propeptide (P1NP), increased significantly (relative to control) in the D + Q group at both 2 weeks (+16%, P = 0.020) and 4 weeks (+16%, P = 0.024), but was not different from control at 20 weeks”
Quote in the paperNot yet classified - Finding
Baseline SASP factors were generally higher in the T3 group than in the T1/T2 group.
“baseline SASP factors were generally higher in the T3 group versus the T1/T2 group”
Quote in the paperNot yet classified - Finding
In the T3 group, changes in SASP factors did not differ between the control and D + Q groups.
“changes in SASP factors did not differ between the control and D + Q groups”
Quote in the paperNot yet classified
- Finding
The authors note that intermittent D + Q may preferentially stimulate bone formation over inhibiting bone resorption in humans.
“in humans, senolytics (or at least, D + Q with our monthly dosing regimen) may preferentially stimulate bone formation over inhibiting bone resorption”
Quote in the paperNot yet classified - Finding
In exploratory analyses, the highest tertile of T cell p16 mRNA levels showed an increase in radius BMD at 20 weeks after D + Q treatment.
“radius BMD at 20 weeks, which increased by 2.7% in response to D + Q relative to control (P = 0.004) in the T3 group”
Quote in the paperNot yet classified - Finding
The authors state that the study was the largest RCT of sustained intermittent senolytic administration in generally healthy older women.
“Our study represents the largest (n = 60) RCT of sustained intermittent administration of a senolytic regimen to generally healthy older women.”
Quote in the paperNot yet classified - Finding
The trial's exploratory analyses suggest that the skeletal response to senolytic therapy depends on the underlying senescent cell burden.
“our findings support the hypothesis that the skeletal, and perhaps nonskeletal, response to a senolytic intervention depends on the existing senescent cell burden.”
Quote in the paperNot yet classified - Finding
The trial found that intermittent D + Q did not reduce bone resorption in the overall group of postmenopausal women.
“intermittent D + Q treatment did not reduce bone resorption in the overall group of postmenopausal women.”
Quote in the paperNot yet classified - Finding
No serious adverse events were observed in the trial.
“No serious adverse events were observed.”
Quote in the paperNot yet classified - Method
The study compared D + Q with control over 20 weeks in 60 postmenopausal women.
“We conducted a 20-week, phase 2 RCT comparing D + Q with control for improving bone turnover markers in 60 postmenopausal women.”
Quote in the paperNot yet classified - Method
The investigators measured 36 SASP factors at baseline and 2 weeks postdosing in additional analyses.
“we measured a panel of 36 SASP factors at baseline and 2 weeks postdosing.”
Quote in the paperNot yet classified - Method
The investigators hypothesized that women with a higher baseline senescent cell burden would be more likely to respond to a senolytic intervention.
“We hypothesized that women with a high basal senescent cell burden would be more likely to respond to a senolytic intervention”
Quote in the paperNot yet classified - Method
The primary endpoint was the percentage change in serum CTx from baseline over 20 weeks.
“The primary study endpoint was the percentage change in CTx from baseline over 20 weeks.”
Quote in the paperNot yet classified - Method
Secondary endpoints included changes in serum P1NP, serum CTx at 2, 4 and 20 weeks, BMD by DXA, and safety, tolerability and circulating SASP factors.
“Secondary endpoints included changes in serum P1NP, as well as in serum CTx at 2, 4 and 20 weeks. In addition, we assessed percentage changes in BMD by DXA (radius, femur neck and lumbar spine) at 20 weeks. Additional endpoints were safety, tolerability and circulating SASP factors.”
Quote in the paperNot yet classified - Method
Eligible participants were women older than 60 years with T cell p16 mRNA levels above the 95th percentile of young control women.
“we selected women aged >60 years with a senescent cell burden based on p16 mRNA expression in peripheral blood T cells greater than the 95th percentile of young control women aged 22–31 years.”
Quote in the paperNot yet classified - Method
The study used an open-label design because over-encapsulating the medications to ensure double-blinding was cost-prohibitive.
“over-encapsulating all study medications to ensure double-blinding proved to be cost-prohibitive so, in this initial ‘proof-of-concept’ study, we elected to use an open-label design”
Quote in the paperNot yet classified - Method
The study was a phase 2 randomized controlled trial of intermittent dasatinib plus quercetin in postmenopausal women.
“we conducted a phase 2 randomized controlled trial of intermittent administration of the senolytic combination dasatinib plus quercetin (D + Q) in postmenopausal women”
Quote in the paperNot yet classified - Method
T cell p16 mRNA was measured at baseline in CD3+ peripheral blood T cells by qPCR.
“At baseline, morning fasting peripheral whole blood (10 ml) was obtained from the participants for measuring p16 mRNA in CD3+ peripheral blood T cells via qPCR.”
Quote in the paperNot yet classified - Method
D + Q was administered orally on an intermittent schedule every 28 days over 20 weeks for five dosing sessions.
“D + Q was taken orally on an intermittent schedule with no-therapy periods in between doses, repeated every 28 days over 20 weeks, resulting in five total dosing sessions throughout the entire intervention”
Quote in the paperNot yet classified - Method
The trial monitored withdrawals and adverse events and used the Common Terminology Criteria for Adverse Events for reporting.
“We monitored and rigorously documented all participants who withdrew from the study, the reasons for withdrawal and all adverse events (serious and nonserious).”
Quote in the paperNot yet classified - Background
The abstract describes preclinical evidence that senescent cells accumulate with aging and that senolytics delay multiple age-related morbidities, including bone loss.
“Preclinical evidence demonstrates that senescent cells accumulate with aging and that senolytics delay multiple age-related morbidities, including bone loss.”
Quote in the paperNot yet classified - Method
The study randomized 60 eligible postmenopausal women aged 60 to 90 years to control or D + Q.
“We randomized 60 eligible postmenopausal women (follicle-stimulating hormone >20 IU l−1; sex/gender based on self-reporting) aged 60–90 years to one of two groups: control or D + Q.”
Quote in the paperNot yet classified
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Intraocular study counted as systemic administration
MinorThe discussion includes the diabetic macular edema study among prior studies of systemic senolytic administration, but the paper earlier describes that treatment as a single intraocular injection.
“Previous studies of systemic administration of senolytics have not included a control group, recruited only a limited number of patients with diabetes-associated chronic kidney disease (n = 9)32, idiopathic pulmonary fibrosis (n = 14)33, dementia (n = 5)11 or diabetic macular edema (n = 8)12”
“a single intraocular administration of another senolytic compound, the BCL-xL inhibitor UBX1325, was safe and improved visual acuity in five of eight patients with diabetic macular edema”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Cites a retracted work: 10.1016/j.fitote.2015.09.018
InfoThe cited work was retracted on 2024-12-28 (notice 10.1016/j.fitote.2024.106320), not before this paper was published (2024-07-02).
Cited work 10.1016/j.fitote.2015.09.018 · retracted 2024-12-28 · notice 10.1016/j.fitote.2024.106320 · this paper published 2024-07-02
“D’Andrea, G. Quercetin: a flavonol with multifaceted therapeutic applications? Fitoterapia 106, 256–271 (2015).”
Cites
1 retracted
RETRACTED: Quercetin: A flavonol with multifaceted therapeutic applications?
D’Andrea, G. (2015) · Fitoterapia · doi:10.1016/j.fitote.2015.09.018 · Cited by 729 · see citing works
RetractedThe serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508 · cited 1× · see citing works
“Cellular senescence was first described by Hayflick and Moorhead in 1961 as an in vitro phenomenon, whereby normal human fibroblasts stopped proliferating and entered a state of irreversible growth arrest 1 .”
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670 · cited 1× · see citing works
“Moreover, the demonstration in old mice that clearing senescent cells using a genetic approach extended health span and lifespan 4,5 generated intense interest in therapeutically targeting senescent cells in humans to prevent or delay age-related comorbidities as a group 6 .”
Self-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,891 · see citing works
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,562 · cited 2× · see citing works
“…the translation of these findings to humans was the identification of compounds (‘senolytics’) that targeted survival pathways unique to senescent cells, resulting in their selective killing and beneficial effects in old mice similar to those observed with genetic clearance of senescent cells 7,8 .”
Self-citationClearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819 · cited 1× · see citing works
“…the translation of these findings to humans was the identification of compounds (‘senolytics’) that targeted survival pathways unique to senescent cells, resulting in their selective killing and beneficial effects in old mice similar to those observed with genetic clearance of senescent cells 7,8 .”
Cellular senescence and the senescent secretory phenotype: therapeutic opportunities
Tchkonia, T., Zhu, Y., van Deursen, J., Campisi, J., & Kirkland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64098 · Cited by 1,774 · cited 2× · see citing works
“…are mediated via modulation of sclerostin levels (or possibly other effects on Wnt signaling in bone), the advantage of senolytics would be their potential nonskeletal effects on frailty, metabolic dysfunction and other age-associated morbidities 16 , in addition to their skeletal actions.”
Self-citationDasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H. M., Shah, N. P., Hochhaus, A., Cortes, J. E., Shah, S. A., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasqüini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,572 · see citing works
Ink4a/Arf expression is a biomarker of aging
Krishnamurthy, J., Torrice, C., Ramsey, M. R., Kovalev, G. I., Al-Regaiey, K., Su, L., & Sharpless, N. E. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22475 · Cited by 1,486 · see citing works
Hickson, L. J., Langhi Prata, L. G. P., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., Herrmann, S. M., Jensen, M. D., Jia, Q., Jordan, K. L., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.069 · Cited by 1,383 · cited 1× · see citing works
“…senolytics have not included a control group, recruited only a limited number of patients with diabetes-associated chronic kidney disease ( n = 9) 32 , idiopathic pulmonary fibrosis ( n = 14) 33 , dementia ( n = 5) 11 or diabetic macular edema ( n = 8) 12 and were focused primarily on safety or…”
Self-citationSenolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Justice, J. N., Nambiar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., Prata, L., Masternak, M. M., Kritchevsky, S. B., Musi, N., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.052 · Cited by 1,261 · see citing works
Self-citationRomosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258 · see citing works
Targeting cellular senescence prevents age-related bone loss in mice
Farr, J. N., Xu, M., Weivoda, M. M., Monroe, D. G., Fraser, D. G., Onken, J. L., Negley, B. A., Sfeir, J. G., Ogrodnik, M. B., Hachfeld, C. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4385 · Cited by 1,182 · cited 9× · see citing works
“…that our previous studies in aged mice had demonstrated a reduction in bone resorption and increase in bone formation following seno-lytic treatment 13,14 , the choice of whether to assign CTx or P1NP as the primary endpoint was entirely arbitrary, particularly in the absence of any previous human…”
InfluentialSelf-citationCellular senescence and senolytics: the path to the clinic
Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01923-y · Cited by 1,105 · cited 2× · see citing works
“Although preclinical studies have found beneficial effects of clearing senescent cells in aged mice on measures of frailty, cognition, glucose tolerance, cardiovascular function and others 6 , we chose bone metabolism as an outcome for several reasons.”
Self-citationCellular Senescence in Aging Primates
Herbig, U., Ferreira, M., Condel, L., Carey, D., & Sedivy, J. M. (2006) · Science · doi:10.1126/science.1122446 · Cited by 1,101 · cited 1× · see citing works
“p16 is a key trigger of cellular senescence 16 , and its expression increases with aging in several rodent and primate tissues 17–19 , suggesting its potential use as a biomarker of mammalian aging.”
A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues
Saul, D., Kosinsky, R. L., Atkinson, E. J., Doolittle, M. L., Zhang, X., LeBrasseur, N. K., Pignolo, R. J., Robbins, P. D., Niedernhofer, L. J., Ikeno, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32552-1 · Cited by 1,060 · cited 1× · see citing works
“…reported that administration of D + Q to patients with diabetic kidney disease reduced expression (using a global gene set enrichment analysis) of a senescence/SASP gene set (SenMayo) in adipose tissue biopsies, analysis of peripheral blood mononuclear cells failed to find a similar signal 26 .”
Self-citationZhu, Y., Doornebal, E. J., Pirtskhalava, T., Giorgadze, N., Wentworth, M., Fuhrmann-Stroissnigg, H., Niedernhofer, L. J., Robbins, P. D., Tchkonia, T., & Kirkland, J. L. (2017) · Aging · doi:10.18632/aging.101202 · Cited by 757 · see citing works
Self-citationThe senescence-associated secretory phenotype and its regulation
Lopes-Paciencia, S., Saint-Germain, E., Rowell, M.-C., Ruiz, A. F., Kalegari, P., & Ferbeyre, G. (2019) · Cytokine · doi:10.1016/j.cyto.2019.01.013 · Cited by 601 · cited 1× · see citing works
“…in mice, also established that accumulation of senescent cells with aging contributed to multiple age-associated comorbidities by virtue of their senescence-associated secretory phenotype (SASP), which consists of cytokines, proteases, bioactive lipids and other proinflammatory molecules 3 .”
Identification of senescent cells in the bone microenvironment
Farr, J. N., Fraser, D. G., Wang, H., Jaehn, K., Ogrodnik, M. B., Weivoda, M. M., Drake, M. T., Tchkonia, T., LeBrasseur, N. K., Kirkland, J. L., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2892 · Cited by 562 · cited 1× · see citing works
“p16 is a key trigger of cellular senescence 16 , and its expression increases with aging in several rodent and primate tissues 17–19 , suggesting its potential use as a biomarker of mammalian aging.”
Self-citationLiu, Y., Sanoff, H. K., Cho, H., Burd, C. E., Torrice, C., Ibrahim, J. G., Thomas, N. E., & Sharpless, N. E. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00489.x · Cited by 509 · see citing works
In Vivo Assessment of Bone Quality in Postmenopausal Women With Type 2 Diabetes
Farr, J. N., Drake, M. T., Amin, S., Melton, L. J., McCready, L. K., & Khosla, S. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2106 · Cited by 499 · see citing works
Self-citationBone Turnover Markers: Basic Biology to Clinical Applications
Schini, M., Vilaça, T., Gossiel, F., Salam, S., & Eastell, R. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac031 · Cited by 415 · cited 1× · see citing works
“…frailty or cognition, which can be difficult to measure, may include subjective features and require large numbers of participants and prolonged interventions, bone turnover markers are simple, objective measures of a biological outcome that respond within only a few weeks to an intervention 15 .”
The senescence-associated secretome as an indicator of age and medical risk
Schafer, M. J., Zhang, X., Kumar, A., Atkinson, E. J., Zhu, Y., Jachim, S., Mazula, D. L., Brown, A. K., Berning, M., Aversa, Z., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133668 · Cited by 401 · cited 2× · see citing works
“These assays were performed according to the manufacturer’s protocols and analyzed on a MAGPIX System (Merck Millipore), as described previously 24 .”
Self-citationSenolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial
Gonzales, M. M., Garbarino, V. R., Kautz, T. F., Palavicini, J. P., Lopez-Cruzan, M., Dehkordi, S. K., Mathews, J. J., Zare, H., Xu, P., Zhang, B., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02543-w · Cited by 310 · cited 2× · see citing works
“In an uncontrolled study, Gonzales et al. 11 reported data on the safety and biodistribution of the senolytic cocktail, D + Q 7 , in five patients with mild Alzheimer’s disease.”
Self-citationQuercetin pharmacokinetics in humans
Moon, Y. J., Wang, L., DiCenzo, R., & Morris, M. E. (2008) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.605 · Cited by 287 · see citing works
Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer
Sanoff, H. K., Deal, A. M., Krishnamurthy, J., Torrice, C., Dillon, P., Sorrentino, J., Ibrahim, J. G., Jolly, T. A., Williams, G., Carey, L. A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju057 · Cited by 283 · cited 1× · see citing works
“…to increase with age 20 , physical inactivity 20 and smoking 20 ; to be associated with plasma interleukin-6 (IL-6) levels (a marker of human frailty) 20 ; to increase following chemotherapy; 30 and to predict length of hospital stay after coronary artery bypass surgery in older adults 31 .”
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Caldemeyer, L. E., Dugan, M. J., Edwards, J., et al. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0309-2 · Cited by 173 · see citing works
The costs and benefits of senotherapeutics for human health
Raffaele, M., & Vinciguerra, M. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00300-7 · Cited by 140 · cited 1× · see citing works
“…or macular degeneration and diabetic kidney disease, idiopathic pulmonary fibrosis, Alzheimer’s disease, among others) have a higher senescent cell burden than normal tissues 23 , these diseased tissues within an individual may be more susceptible to senolytic treatments than normal tissues.”
Sympathetic β1-adrenergic signaling contributes to regulation of human bone metabolism
Khosla, S., Drake, M. T., Volkman, T. L., Thicke, B. S., Achenbach, S. J., Atkinson, E. J., Joyner, M. J., Rosen, C. J., Monroe, D. G., & Farr, J. N. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122151 · Cited by 132 · see citing works
Self-citationChanges in Bone Mass and Bone Turnover Following Distal Forearm Fracture
Ingle, B. M., Hay, S. M., Bottjer, H. M., & Eastell, R. (1999) · Osteoporosis International · doi:10.1007/s001980050246 · Cited by 128 · see citing works
Crespo‐Garcia, S., Fournier, F., Diaz-Marin, R., Klier, S. M., Ragusa, D., Masaki, L., Cagnone, G., Blot, G., Hafiane, I., Dejda, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02802-4 · Cited by 108 · cited 3× · see citing works
“More recently, Crespo-Garcia et al. 12 demonstrated that a single intraocular administration of another senolytic compound, the BCL-xL inhibitor UBX1325, was safe and improved visual acuity in five of eight patients with diabetic macular edema 24 weeks following injection, although no formal…”
Cellular senescence and the skeleton: pathophysiology and therapeutic implications
Khosla, S., Farr, J. N., & Monroe, D. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154888 · Cited by 102 · cited 1× · see citing works
“Subsequently, extensive studies have demonstrated that senescence occurs not only in vitro, but also in vivo and is not limited to proliferating cells but also occurs in quiescent, terminally differentiated cells such as neurons, hepatocytes, cardiomyocytes and osteocytes 2 .”
Self-citationClinical Pharmacokinetics and Pharmacodynamics of Dasatinib
Levêque, D., Becker, G., Bilger, K., & Natarajan-Amé, S. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00872-4 · Cited by 90 · see citing works
Local senolysis in aged mice only partially replicates the benefits of systemic senolysis
Farr, J. N., Saul, D., Doolittle, M. L., Kaur, J., Rowsey, J. L., Vos, S. J., Froemming, M. N., Lagnado, A. B., Zhu, Y., Weivoda, M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162519 · Cited by 81 · cited 6× · see citing works
“…our previous studies in aged mice had demonstrated a reduction in bone resorption and increase in bone formation following seno-lytic treatment 13,14 , the choice of whether to assign CTx or P1NP as the primary endpoint was entirely arbitrary, particularly in the absence of any previous human…”
InfluentialSelf-citationFarr, J. N., Charkoudian, N., Barnes, J. N., Monroe, D. G., McCready, L. K., Atkinson, E. J., Amin, S., Melton, L. J., Joyner, M. J., & Khosla, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2381 · Cited by 79 · cited 2× · see citing works
“As we have established 29,39,40 , serum P1NP and CTx were measured with standard, validated assays: P1NP by radioimmunoassay (Orion Diagnostica, coefficient of variation <9%); and CTx by one-step ELISA (Nordic Bioscience Diagnostics, coefficient of variation <8%).”
InfluentialSelf-citationHormonal and systemic regulation of sclerostin
Drake, M. T., & Khosla, S. (2017) · Bone · doi:10.1016/j.bone.2016.12.004 · Cited by 77 · cited 1× · see citing works
“This may be because sclerostin functions primarily as a paracrine factor 25 , so local reductions in sclerostin in the bone microenvironment following senolysis may not be reflected by circulating sclerostin levels.”
Self-citationLow-dose dasatinib rescues cardiac function in Noonan syndrome
Yi, J.-S., Huang, Y., Kwaczala, A. T., Kuo, I. Y., Ehrlich, B. E., Campbell, S. G., Giordano, F. J., & Bennett, A. M. (2016) · JCI Insight · doi:10.1172/jci.insight.90220 · Cited by 48 · see citing works
Lin, Y.-C., Diccianni, M. B., Kim, Y., Lin, H.-H., Lee, C.-H., Lin, R.-J., Joo, S. H., Li, J., Chuang, T.-J., Yang, A.-S., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210507 · Cited by 39 · see citing works
Pustavoitau, A., Barodka, V., Sharpless, N. E., Torrice, C., Nyhan, D., Berkowitz, D. E., Shah, A. S., Bandeen Roche, K. J., & Walston, J. D. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2015.12.003 · Cited by 36 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
From geroscience to precision geromedicine: Understanding and managing aging
Kroemer, G., Maier, A. B., Cuervo, A. M., Gladyshev, V. N., Ferrucci, L., Gorbunova, V., Kennedy, B. K., Rando, T. A., Seluanov, A., Sierra, F., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.011 · Cited by 395 · see citing works
Emerging insights in senescence: pathways from preclinical models to therapeutic innovations
Mansfield, L., Ramponi, V., Gupta, K., Stevenson, T., Mathew, A. B., Barinda, A. J., Herbstein, F., & Morsli, S. (2024) · npj Aging · doi:10.1038/s41514-024-00181-1 · Cited by 91 · see citing works
Millar, C. L., Iloputaife, I., Baldyga, K., Norling, A. M., Boulougoura, A., Vichos, T., Tchkonia, T., Deisinger, A., Pirtskhalava, T., Kirkland, J. L., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105612 · Cited by 88 · see citing works
“14,27,28 To date, four human studies administering DQ as a combination senolytic therapy have been completed in various populations, including idiopathic pulmonary fi brosis, 29 diabetic kidney disease, 30 age-related osteoporosis, 31 and Alzheimer ’ s disease.”
Self-citationMacrophages: Subtypes, Distribution, Polarization, Immunomodulatory Functions, and Therapeutics
Peng, M., Li, N., Wang, H., Li, Y., Liu, H., Luo, Y., Lang, B., Zhang, W., Li, S., Tian, L., et al. (2025) · MedComm · doi:10.1002/mco2.70304 · Cited by 95 · see citing works
“In a study assessing the effects of intermittent D + Q on bone metabolism in postmenopausal women, no significant reduction in overall bone resorption was observed (NCT04313634) [387], highlighting the need for optimized dosing regimens.”
Advances in the management of osteoporosis
Hoong, C. W. S., Saul, D., Khosla, S., & Sfeir, J. G. (2025) · BMJ · doi:10.1136/bmj-2024-081250 · Cited by 73 · see citing works
“P1NP increases rapidly within two weeks and peaks within one month, and it is coupled with suppression of CTX maintained over 12 months.”
InfluentialSelf-citationImmune Aging in Rheumatoid Arthritis
Weyand, C. M., & Goronzy, J. J. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43105 · Cited by 55 · see citing works
“18 Another class of SASP-targeting drugs are the senomorphics, designed to modify SASP factors in vivo.”
Teng, H., Xiao, H., Li, X., Huang, J., Zhang, B., & Zeng, M. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.105000 · Cited by 46 · see citing works
Klepacki, H., Kowalczuk, K., Łepkowska, N., & Hermanowicz, J. M. (2025) · Cells · doi:10.3390/cells14130942 · Cited by 44 · see citing works
Subedi, S., Guntipally, M., Suwal, N., Thapa, R., Bashyal, S., Panth, N., Gupta, G., MacLoughlin, R. J., Oliver, B. G. G., Dua, K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102813 · Cited by 33 · see citing works
Kritchevsky, S. B., & Cummings, S. R. (2025) · JAMA · doi:10.1001/jama.2025.11289 · Cited by 38 · see citing works
Targeting DNA damage in ageing: towards supercharging DNA repair
Bujarrabal-Dueso, A., Garinis, G. A., Robbins, P. D., Vijg, J., & Schumacher, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01212-6 · Cited by 30 · see citing works
“Although in a recent phase II trial in postmenopausal women D+Q failed to reduce bone resorption, participants with the highest levels of senescence markers did benefit, suggesting that stratification according to senescence burden could enhance treatment efficacy 86 .”
Recent Advances in Osteoporosis Therapeutics
Sølling, A. S., Langdahl, B. L., & Cosman, F. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-040555 · Cited by 38 · see citing works
A new clinical age of aging research
Zhang, Z., Yang, R., Zi, Z., & Liu, B. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.08.004 · Cited by 25 · see citing works
Anti-senescence therapies: a new concept to address cardiovascular disease
Stojanović, S. D., Thum, T., & Bauersachs, J. K. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf030 · Cited by 28 · see citing works
“Early feasibility trials in idiopathic pulmonary fibrosis, 123,124 diabetic nephropathy, 125 Alzheimer’s disease, 28 and osteopenia 23 are under-powered for the evaluation of clinical outcomes but show tolerability with trends towards improved physical fitness and reduction of senescence, SASP, and…”
A Critical Appraisal of the Utility of Targeting Therapy-Induced Senescence for Cancer Treatment
Saleh, T., Greenberg, E. F., Faber, A. C., Harada, H., & Gewirtz, D. A. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-2219 · Cited by 26 · see citing works
Dasatinib and Quercetin Limit Gingival Senescence, Inflammation, and Bone Loss
Rattanaprukskul, K., Xia, X.-J., Hysa, M., Jiang, M., Hung, M., Suslavich, S. F., & Sahingur, S. E. (2025) · Journal of Dental Research · doi:10.1177/00220345241299789 · Cited by 23 · see citing works
“Cellular senescence is the central hallmark of aging and driver of several chronic diseases such as diabetes, cardiovascular disease, kidney disease, Alzheimer’s disease, and osteoporosis (Chaib et al. 2022; Farr et al. 2024).”
Characterization of Human Senescent Cell Biomarkers for Clinical Trials
Farr, J. N., Monroe, D. G., Atkinson, E. J., Froemming, M. N., Ruan, M. M., LeBrasseur, N. K., & Khosla, S. (2025) · Aging Cell · doi:10.1111/acel.14489 · Cited by 24 · see citing works
Self-citationEndothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice
Suda, M., Chaib, S., Prata, L. G. P. L., Zhu, Y. Z., Tripathi, U., Paul, K. H., Palmer, A. K., Pirtskhalava, T., Kulshreshtha, V., Inman, C. L., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.10.009 · Cited by 24 · see citing works
Self-citationMurray, K. O., Mahoney, S. A., Ludwig, K. R., Miyamoto-Ditmon, J., VanDongen, N. S., Banskota, N., Herman, A. B., Seals, D. R., Mankowski, R. T., Rossman, M. J., et al. (2025) · Aging Cell · doi:10.1111/acel.70114 · Cited by 19 · see citing works
Dasatinib and Quercetin Mitigate Age‐Related Alveolar Bone Inflammaging and Neutrophil Infiltration
Tang, J., Li, J.-Y., Hou, Z., He, R., Li, B.-Z., Gong, J., Xie, Y., Meng, W.-R., Liu, Y.-K., Ouchi, T., et al. (2025) · Oral Diseases · doi:10.1111/odi.15291 · Cited by 16 · see citing works
Yang, B., Yang, K., Xi, R., Li, S., Chen, J., & Wu, Y. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103716 · Cited by 12 · see citing works
“This regimen has potential therapeutic effects in alleviating age-related diseases, such as Alzheimer ’ s disease and bone loss [55,56].”
Bian, X., Snow, Z. K., Zinn, C. J., Bratulin, A. L., Elhusseiny, K. M., Tchkonia, T., Kirkland, J. L., Zhu, Y., Khosla, S., Kim, S. R., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106124 · Cited by 13 · see citing works
“36 These investigations were extended to an early-Research”
Self-citationSenescence of skeletal stem cells and their contribution to age-related bone loss
Wölfel, E. M., Guerra, P. F., Nørgård, M. Ø., Jeromdesella, S., Kjær, P. K., Elkjaer, A. S., Kassem, M. S., & Figeac, F. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111976 · Cited by 12 · see citing works
Gao, X., Hu, Y., Zhang, Y., Huang, Y., Zhang, G., Zhang, X., Zhou, Y., & Zhang, D. (2025) · Science Advances · doi:10.1126/sciadv.adr2833 · Cited by 11 · see citing works
“Comparison studies were performed with the clinically common combination treatment using D + Q ( 6 , 35 , 36 ).”
Biomarkers of Cellular Senescence in Type 2 Diabetes Mellitus
Hoong, C. W. S., Farr, J. N., Monroe, D. G., White, T. A., Atkinson, E. J., Tweed, A. J., Palmer, A. K., LeBrasseur, N. K., Sfeir, J. G., & Khosla, S. (2025) · Aging Cell · doi:10.1111/acel.70120 · Cited by 10 · see citing works
Self-citationTranslating cellular senescence research into clinical practice for metabolic disease
Chaib, S., Palmer, A. K., Wyles, S. P., Musi, N., Kirkland, J. L., & Tchkonia, T. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01187-9 · Cited by 14 · see citing works
“…pilot trials have shown that senescent cells can be cleared in humans both in tissues and systemically 28 , senolytics are well tolerated (as shown in multiple trials) and, most importantly, individuals with high senescent cell burden seem to benefit the most from senolytic therapies 81,167,168 .”
Self-citationColonic Aging and Colorectal Cancer: An Unignorable Interplay and Its Translational Implications
Yin, Q., Qin, F.-C., Gan, F., Zhao, G., Chen, R., Wen, Y., Hua, X., Zeng, F.-G., Zhang, Y.-Z., Xiao, Y.-L., et al. (2025) · Biology · doi:10.3390/biology14070805 · Cited by 16 · see citing works
“Biomarkers like plasma IL-6, TNF-alpha, and GDF15 (components of SASP) are measured to monitor the effectiveness of these treatments and the systemic senescent burden in trials for conditions like idiopathic pulmonary fibrosis, osteoarthritis, and Alzheimer’s disease [182].”
Falvino, A., Bonanni, R., Tarantino, U., Tancredi, V., & Cariati, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157573 · Cited by 11 · see citing works
“…is more effective in stimulating bone formation, like the action of some anabolic drugs such as romosozumab, rather than in inhibiting resorption, highlighting the importance of investigating the effects of further combinations of senotherapeutics in different modes of administration [113].”
InfluentialCai, Z., Wang, H., Hu, J., Qu, C., Chen, S., Liu, X., & Fan, C. (2025) · The American Journal of Sports Medicine · doi:10.1177/03635465251381763 · Cited by 10 · see citing works
Functional Features of Senescent Cells and Implications for Therapy
Kirichenko, T. V., Markina, Y. V., Markin, A. M., Vasilyev, V. S., Hua, H., Li, D., Woo, A. Y., Deev, R. V., Eremin, I. I., & Kotenko, K. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115390 · Cited by 9 · see citing works
“The senolytic activity of the combination of dasatinib and quercetin was evaluated in clinical studies in postmenopausal women, in patients with Alzheimer’s disease, and in patients with idiopathic pulmonary fibrosis [73–75].”
Kontoghiorghes, G. J. (2025) · Nutrients · doi:10.3390/nu17203270 · Cited by 9 · see citing works
“Some of these conditions included tissue repair in bone–muscle–tendon regeneration in aging [167], bone loss in postmenopausal women [168,169], polycystic ovary syndrome [170], inflammatory bowel disease [171], diabetes and other metabolic disorders [172], non-alcoholic fatty liver disease…”
Jia, L., Xiao, H., Hao, Z., Sun, S., Zhao, W., Gong, Z., Gu, W., & Wen, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.119921 · Cited by 8 · see citing works
Horikawa, I., Yamada, L., Harris, B. T., & Harris, C. C. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.06.031 · Cited by 7 · see citing works
Rao, X., & Cai, X. T. (2026) · The FASEB Journal · doi:10.1096/fj.202505069r · Cited by 7 · see citing works
Cellular senescence in age-related musculoskeletal diseases
Xiong, J., Guo, Q., & Luo, X. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1125-7 · Cited by 10 · see citing works
Li, Y., Yang, Y., Xia, D., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103804 · Cited by 6 · see citing works
“Moreover, recent clinical trials have demonstrated the efficacy of senolytic therapy in promoting osteogenesis. however, its capacity to inhibit osteoclast activity is limited [36].”
Towards a personalized approach in senolytic trials
Khosla, S., Monroe, D. G., & Farr, J. N. (2025) · Nature Aging · doi:10.1038/s43587-025-00964-5 · Cited by 6 · see citing works
Self-citationEffect of senolytic drugs in young female mice chemically induced to estropause
Ávila, B. M., Zanini, B. M., Luduvico, K. P., Oliveira, T. L., Hense, J. D., Garcia, D. N., Prosczek, J. B., Stefanello, F. M., Cruz, P. H. F. D., Giongo, J. L., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123073 · Cited by 6 · see citing works
Schulz, N., Asendorf, T., van Wijnen, P., Wilhelmi, T., Müller‐Ladner, U., Lange, U., & Klemm, P. (2025) · Calcified Tissue International · doi:10.1007/s00223-025-01410-9 · Cited by 7 · see citing works
Targeting senescent microglia in progressive multiple sclerosis: a geroscience-informed approach
Atkinson, J., Dokiburra, A., Groover, H., Godbout, J. P., Segal, B. M., & Zhang, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1681724 · Cited by 6 · see citing works
Senotherapeutics for metabolic disease and diabetic complications
Palmer, A. K., Spinelli, R., Prata, L. G. P. L., Chaib, S., Suda, M., Tchkonia, T., Smith, U., & Kirkland, J. L. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70039 · Cited by 5 · see citing works
“Clinical trials of senolytics for Alzheimer’s disease and age-related osteoporosis suggest early promise [141–144].”
Self-citationKourti, M., & Kontoghiorghes, G. J. (2025) · Antioxidants · doi:10.3390/antiox15010015 · Cited by 8 · see citing works
“No consistent alterations in systemic iron indices have been reported in the D+Q trials, although both quercetin and dasatinib possess metal-binding ligands [14], and quercetin itself possesses iron-binding and antioxidant properties that may contribute to its senomorphic actions [14,263,264].”
Insights into the therapeutic strategies for aging and aging-associated diseases
Dong, R., Wu, Q., Kan, J., Fu, C., Sorrentino, V., Chow, A., Lei, Y., Wu, D., Xu, Z., Du, J., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02662-z · Cited by 8 · see citing works
Cellular senescence in skeletal diseases: A bibliometric analysis from 2007 to 2024.
Zhang, X.-R., Yang, B., Xu, X.-P., Zhang, Z.-R., Tao, Z., Zhang, W.-J., Zhang, Z., & Zhou, X.-H. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112857 · Cited by 5 · see citing works
Kim, S. J., Batra, C., Yoshii, H., Hamada, Y., Ueki, Y., Eckert, G. J., John, V., & Kittaka, M. (2025) · The Journal of Periodontology · doi:10.1002/jper.11393 · Cited by 7 · see citing works
Cai, D., Li, Z., Gao, W., Liu, J., Qi, X., Jin, J., Zhang, Y., Zhang, Q., Xiao, L., & Xiao, Y. (2025) · ACS Nano · doi:10.1021/acsnano.5c14201 · Cited by 4 · see citing works
Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics
Garzon-Escamilla, N., Medina-Cardena, M., Roy, P., Trent, J., Jamous, J., Somesan, Y., & Denslow, S. (2026) · Biomedicines · doi:10.3390/biomedicines14020316 · Cited by 4 · see citing works
“Moreover, ongoing clinical trials are evaluating the feasibility, safety, and tolerability of D+Q therapies for modulating AD progression, for bone loss in postmenopausal women, and to improve physical function in patients with idiopathic pulmonary fibrosis [143,144,158].”
Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming
Zhang, W., Song, S., Zhang, Y., Pan, Y., Hu, D., & Wang, Y. (2026) · npj Aging · doi:10.1038/s41514-026-00355-z · Cited by 6 · see citing works
“An early-phase pilot study in IPF suggested modest functional trends 36 , and a Phase 2 trial in post-menopausal women showed limited biomarker changes with subtle or no signi fi cant clinical improvements in bone mass 37 .”
Huang, Y., Zhou, Y., He, Z., Yang, J., Gu, J., Cui, B., Li, S., Deng, H., Zhao, W., Yang, X., et al. (2025) · Inflammation · doi:10.1007/s10753-024-02213-0 · Cited by 4 · see citing works
Aging and anti-aging strategies: A review of past and future therapeutics
Wei, Y., Xiong, B., Song, Z., Zhong, S., Zheng, N., Zhang, A., Chen, Y., & Sun, H. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118340 · Cited by 4 · see citing works
Khan, T., McFall, D. J., Hussain, A. I., Frayser, L. A., Casilli, T. P., Steck, M. C., Sánchez-Brualla, I., Kuehn, N. M., Cho, M., Barnes, J. A., et al. (2025) · Annals of Neurology · doi:10.1002/ana.78118 · Cited by 5 · see citing works
Proteolysis targeting chimeras as senolytics: An emerging senotherapy for combating aging
Cruickshank‐Taylor, A. B., Kozora, J. S., Carew, J. S., Nawrocki, S. T., & Wang, W. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103752 · Cited by 4 · see citing works
Targeting Genome Stability to Mitigate Human Aging and Disease
Toiber, D., & Schumacher, B. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-042624-105942 · Cited by 4 · see citing works
Growth differentiation factor 15 and the risk of hip fracture in older adults
Mattia, L., Patel, S., Webber, K., Pugliese, G., Cummings, S. R., & Eastell, R. (2026) · JBMR Plus · doi:10.1093/jbmrpl/ziaf192 · Cited by 3 · see citing works
Cancer and aging: complex associations and therapeutic targets
Liang, J., Zang, S., Zhe, W. A. N. G., & Zhang, R. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00423-6 · Cited by 4 · see citing works
Senescent cells: a therapeutic target in correction of aging
Kirichenko, T. V., Markina, Y. V., Markin, A. M., Eremin, I. I., & Deev, R. V. (2024) · Восстановительные биотехнологии, профилактическая, цифровая и предиктивная медицина. · doi:10.17116/rbpdpm2024103153 · Cited by 3 · see citing works
Game changer: Navigating between challenges and hopes in geropharmacology
Chen, Q., Hartman, R., Dankiv, L., Yan, E., Young, L. H., & Barsotti, R. (2025) · Advances in pharmacology · doi:10.1016/bs.apha.2025.02.007 · Cited by 2 · see citing works
Devi, K., Shanmugarajan, T. S., & Ravichandiran, V. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266387622250519052501 · Cited by 2 · see citing works
The Role of Senolytics in Osteoporosis
Chen, E., Zhang, J., Chen, H., & Li, W. (2025) · Biomolecules · doi:10.3390/biom15081176 · Cited by 6 · see citing works
“…ID: NCT04313634) conducted by the Mayo Clinic demonstrated that levels of procollagen type I N-terminal propeptide (PINP) were higher in the dasatinib and quercetin treatment group at weeks 2 and 4 compared to controls, although no significant differences were observed by week 20 [135].”
Liu, Q., Xie, Z., Li, W., Li, M., & Qi, Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1714824 · Cited by 2 · see citing works
The regeneration model of aging and its practical implications
Dassoff, E. (2026) · Discover Medicine · doi:10.1007/s44337-025-00558-5 · Cited by 2 · see citing works
CD8+ T cell aging, senescence, and related disease
He, Z., Guo, F., Zhao, Q., & Lu, W. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3101-7 · Cited by 2 · see citing works
Yang, Q., Xie, C., Luo, Z., Huang, W., Zhang, Z., Ren, K., Xu, X., HE, H., He, M., & Yin, L. (2026) · Redox Report · doi:10.1080/13510002.2026.2632434 · Cited by 4 · see citing works
“This feasibility is grounded in its established safety and tolerability profile across diverse populations, including patients with pathological conditions [25] or post-acute recovery [62], and specific subgroups of healthy individuals [63,64].”
Tagliafico, L., Canevelli, M., Barreto, P. D. S., Cesari, M., Ferrucci, L., Vellas, B. J., & Rolland, Y. (2026) · The Journal of Frailty & Aging · doi:10.1016/j.tjfa.2026.100147 · Cited by 2 · see citing works
“Although no overall reduction in bone resorption was observed across the entire patient cohort, a potential therapeutic response was noted among a subsample of individuals with a high burden of senescent cells [34].”
High‐Salt Diet–Induced Endothelial Dysfunction Is Mediated by Cellular Senescence
do Nascimento, A. F., Luvizotto, R. D. A. M., Costa, R. M., Pimenta, G. F., Bruder‐Nascimento, A., & Bruder-Nascimento, T. B. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.045304 · Cited by 2 · see citing works
“Several clinical trials are now evaluating senolytic drugs for diverse conditions, including bone metabolism disorders, 37 Alzheimer disease, 38 and diabetic macular edema, 39 while preclinical studies have shown therapeutic benefits in models of atherosclerosis and kidney disease.”
Wen, Z. H., Yu, M., Li, S., Zeng, F., Li, J. W., Li, J. W., Liang, G., & Wang, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1855772 · Cited by 2 · see citing works
Hou, J., Chen, K.-X., Xiao, Q.-N., Hu, C., Wei, J., Jiang, Y.-Z., Liu, L., He, C., Huang, M., Jiao, Y., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01130-1 · Cited by 3 · see citing works
“Moreover, recent clinical studies have further confirmed that D+Q therapy demonstrated feasibility, safety and tolerability in mild Alzheimer’s disease 18 and postmenopausal osteoporosis 19 .”
Systemic recalibration and epigenetic resetting as complementary strategies in ageing biology
Li, Y.-Y., & Tay, F. R. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103227 · Cited by 2 · see citing works
Laohajaroensombat, O., Poochanasri, M., & Samakkarnthai, P. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000915 · Cited by 1 · see citing works
Gao, X., Ruzbarsky, J. J., Huard, M., Sajedi, S., Shyu, P. T., Xiao, Z., Force, B. S., White, S., Ayers, J. D., Wang, B., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108016 · Cited by 1 · see citing works
“A recent clinical trial also demonstrated that D+Q did not significantly reduce bone resorption in post-menopausal women despite its effectiveness in decreasing osteoclasts in aged mice [34,54].”
Deconstructing senescence phenotypes in cells of the bone and bone marrow
Hofbauer, L. C., & Rauner, M. (2026) · Journal of Clinical Investigation · doi:10.1172/jci204645 · Cited by 1 · see citing works
“While the overall study did not meet the endpoints, senolysis with dasatinib/quercetin significantly improved bone markers and increased bone mineral density at the radius in those women with the highest senescent cell burden, determined by p16 + T cells (9).”
Ceramic-based biomaterials: Combining regeneration with anti-senescence
Ma, X., Yang, Z., Jin, K., Cao, S., Ma, B., Xiao, Y., & Wu, C. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124195 · Cited by 1 · see citing works
From systemic disease to the eye: Why senescence deserves attention in ocular infections
Maiti, S., & Joseph, J. (2026) · Experimental Eye Research · doi:10.1016/j.exer.2026.111095 · Cited by 1 · see citing works
The gut-bone-inflammation axis: intestinal barrier disruption as a central driver of osteoporosis
Liu, X., Hu, K., & Zhu, T. (2026) · Osteoporosis International · doi:10.1007/s00198-026-07855-4 · Cited by 2 · see citing works
Civitelli, R. (2026) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjag042 · Cited by 1 · see citing works
Senotherapeutics: Emerging pharmacological strategies to target cellular senescence
Nagy, D., Brunner, E., Ekambaram, S., Nagaraja, R. Y., Kordestan, K. V., Patai, R., Kristóf, R., Nagykaldi, M., Chandragiri, S. S., Shanmugarama, S., et al. (2026) · Advances in Translational Research · doi:10.1556/1661.2026.00015 · Cited by 1 · see citing works
Clinical Features of Cellular Senescence Pathways in Severe Asthma
Song, W., Kermani, N. Z., Versi, A., et al. (2026) · Allergy · doi:10.1111/all.70416 · Cited by 1 · see citing works
The immunology behind inflammaging—causes, sources, and mechanisms
Sturmlechner, I., LeBrasseur, N. K., Weyand, C. M., & Goronzy, J. J. (2026) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2026.05.031 · Cited by 3 · see citing works
Self-citationCellular Senescence and Aging: Mechanisms, Disease Convergence, and Therapeutic Frontiers
Cai, G., Ren, J., Wang, L., Wu, Y., Wang, H., Cao, X., Shang, H., Hou, X., Wang, Y., Xue, H., et al. (2026) · MedComm · doi:10.1002/mco2.70827 · Cited by 2 · see citing works
Aging of mesenchymal stem cells in bone aging: Mechanisms, impact, and therapeutic perspectives
Zhou, Z., Wang, H. W., Jin, Z., Wen, B., Wu, T., Zhu, T., & Liu, D. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103240 · Cited by 4 · see citing works
Osteoimmune senescence in aging-related bone diseases
Li, H., Yang, Y., & Zhu, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1892334 · Cited by 5 · see citing works
Geng, Q., Geng, Y., Heng, K., Zhai, J., Song, X., Sha, L., Geng, Y., Nie, P., Liu, F., Zhai, H., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07212-9 · Cited by 1 · see citing works
“Cellular senescence is a hallmark of aging and a significant driver of various chronic diseases, including diabetes, cardiovascular disease, kidney disease, Alzheimer’s disease, and osteoporosis [13, 20, 27, 29, 36].”
Urrego, C. A., Sexton, B., & Kohn, D. H. (2025) · Bone · doi:10.1016/j.bone.2025.117665
Tan, J., Zhu, J., He, Y., Fan, Z., Cai, F., Zhuang, H., Hu, Y., Liu, K., Li, Q., Feng, B., et al. (2025) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-025-09298-0
“…interventions targeting mitochondrial homeostasis in bone cells [40] and senolytic therapies aimed at reducing the load of senescent cells in post-menopausal women [41], could complement early detection efforts by targeting the underlying biological processes that drive bone aging and osteoporosis.”
Partial Reprogramming Is Conserved from Insect to Mammal
Tolwinski, N. S., Fong, S., Shankar, S., & Gruber, J. (2026) · Cells · doi:10.3390/cells15020168
“However, early increases in bone-formation markers were observed, especially among participants with higher baseline senescent-cell burden, indicating a potentially biology-dependent response to senolytic therapy [100].”
Transplanting ANXA1⁻ CD8⁺ Naïve T cells Delay Aging Through SenolysisPreprint
Wu, Y., Guo, S. Z., Zhang, F., Lou, F., Li, Y. Y., Sun, Y., Shen, Q., Zhao, L., Cai, X., Wang, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.21.707223
Chronic low-grade inflammation and primary osteoporosis
Štěpán, J. (2025) · Clinical Osteology · doi:10.36290/clo.2025.023
Multifacet Roles of Cellular Senescence in Cancer: Mechanisms and Therapeutic Implications
Mao, H., Liu, W., Su, Y., Ma, Y., Zhao, X., & Lu, Y. (2026) · MedComm – Oncology · doi:10.1002/mog2.70060
SENOLYTIC COMBINATION OF DASATINIB AND QUERCETIN: A REVIEW OF PRECLINICAL AND CLINICAL STUDIES
Morozov, I. I., Molkanov, N. N., & Kiseleva, N. M. (2025) · Медико-фармацевтический журнал «Пульс» · doi:10.26787/nydha-2686-6838-2026-28-1-49-58
Blomquist, S. A., Kelly, G., D’Adamo, C. R., Han, C., Parker, H., Adães, S., Gardner, C. R., Ardagh, A., Ramer, S., & Scuba, W. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104406 · Cited by 1 · see citing works
“On the other hand, two human studies evaluating dasatinib and quercetin in idiopathic pulmonary fibrosis and in post-menopausal individuals have failed to show significant alteration of SASP markers at the population level [58,59].”
Liu, Y., O’Brien, E. M., Lottinger, C., Perumal, G., Spiller, K. L., & Kuhn, L. T. (2026) · Research Square · doi:10.21203/rs.3.rs-9624236/v1
“Clinical trials of patients taking senolytics and/or senomorphics systemically (orally or by injection) on a continuous basis for osteoporosis management show a moderate benefit 21 .”
Integrating senotherapeutics into transplantation: liver reconditioning in an aging donor pool
Buch, M. L., Esser, H., Perera, H., Zheng, R., Ferreira-González, S., & Forbes, S. J. (2026) · Transplant International · doi:10.3389/ti.2026.16347
“A landmark Phase II randomized controlled trial demonstrated that response to D + Q is influenced by baseline SnC burden, with significant benefits in individuals with high p16 INK4 expression [116].”
Liu, Z., Abulaiti, A., Li, D., Li, J., Wahafu, P., Zhang, Y., Maimaitiming, M., Li, S. Y., Li, G., & Yakufu, M. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103221
Ageing-driven periodontitis: molecular mechanisms and emerging anti-ageing interventions
Li, M. M., Peng, Z., Wang, R., Zheng, Y., Li, S., Kreher, D., Schmalz, G., Han, Q., & Tang, H. (2026) · European journal of medical research · doi:10.1186/s40001-026-04846-3
“However, in terms of clinical data, a recent phase II clinical trial in postmenopausal women (for systemic bone loss) revealed that the improvement in human bone metabolism by D + Q was more limited and transient than that in mouse models [126].”
Mechanism and regulation of programmed cell death in aging-related diseases
Xie, X., & Xu, D. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.06.005 · Cited by 1 · see citing works
From local to systemic: Spinal aging in the multi-organ aging network
Zhang, C., 彭舒畅, Fu, J., Du, Y., Qian, Y., Song, Y., Wang, K. J., & Yang, C. G. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103253
Fehlgeleitete interzelluläre Kommunikation beim Altern und bei chronischen Entzündungen
Großkopf, A., Saemann, L., & Simm, A. (2026) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-026-02619-5
Song, Y., Zhang, R., Zhang, X., Wang, J., Chen, J., & Li, L. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1861883
“Nevertheless, its feasibility will depend on demonstrating skeletal targeting, optimal dosing intervals, safety, and appropriate treatment sequencing, particularly in light of the limited overall benefit observed in the Phase II D + Q trial (Farr et al., 2024).”
InfluentialCorticotropin-releasing factor (CRF) in brain aging: from mitochondrial dysfunction to inflammaging
Yan, M., Hua, L., Jiang, J., Wu, J., Zeng, Z., He, Y., & Chen, Y. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1880569
Toward a context-aware geroscience: integrating structural and social context into aging biology
Bellizzi, K. M., Kuchel, G. A., Redeker, N. S., & Nwakasi, C. C. (2026) · The Gerontologist · doi:10.1093/geront/gnag179
- Authors
- Farr, J. N., Atkinson, E. J., Achenbach, S. J., Volkman, T. L., Tweed, A. J., Vos, S. J., Ruan, M., Sfeir, J., Drake, M. T., Saul, D., Doolittle, M. L., Bancos, I., Yu, K., Tchkonia, T., LeBrasseur, N. K., Kirkland, J. L., Monroe, D. G., & Khosla, S.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Farr, Joshua N.
- Khosla, Sundeep
- ORCID
- Venue
- Nature Medicine
- Published
- 2024-07-02
- Volume
- 30
- Issue
- 9
- Pages
- 2605-2612
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11705617
- OpenAlex
- W4400248879
- Cited by
- 127
- References
- 39
- Citations by year
- 2026: 67 · 2025: 55 · 2024: 5
- FWCI
- 35.85
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute on Aging (R21 AG065868, R01 AG076515, R01 AG055529, R37 AG13925, R33 AG61456, P01 AG062413, R01 AG 062413)
- U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK128552)
- Topics
- Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- senolytics, intermittent dosing, dasatinib, quercetin, bone metabolism, postmenopausal women, bone loss, bone resorption, bone formation, C-terminal telopeptide of type I collagen, P1NP, CDKN2A, bone mineral density, aging
- MeSH terms
- Dasatinib, Senotherapeutics, Aged, Bone and Bones, Bone Resorption, Female, Humans, Middle Aged, Peptide Fragments, Peptides, Procollagen, Quercetin, Biomarkers, Bone Density, Cellular Senescence, Postmenopause, Cyclin-Dependent Kinase Inhibitor p16, Collagen Type I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read (extract-v2) on 2026-09-25.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
